We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel POC Coagulometer with Lab-Like Precision to Revolutionize Coagulation Testing

By LabMedica International staff writers
Posted on 20 Sep 2023

In emergency settings, when patients arrive with a bleed or require urgent surgery, doctors rely solely on clinical judgment to determine if a patient is adequately anticoagulated for reversal treatment. Until now, there was no point-of-care (POC) diagnostic tool available that could provide immediate insights into a patient's coagulation status, especially for those on direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH). Now, a novel POC coagulometer offers a real-time, comprehensive view of a patient's clotting status right in the emergency room.

Perosphere Technologies (Danbury, CT, USA) is engaged in the further development and commercialization of a novel POC coagulometer, known as the Perosphere Technologies POC Coagulometer. This device is unique in its ability to promptly and accurately assess clotting times across various types of anticoagulant medications, including DOACs. It requires only 14 microliters of fresh whole blood and yields easy-to-interpret clotting time results with lab-like precision in 3-8 minutes.

This rapid diagnostic capability can significantly influence timely and accurate treatment decisions, setting a new benchmark for emergency care for patients at risk of bleeding. Its compact design and flexibility make it suitable for use not just in emergency departments and ambulances but also across various healthcare settings like hospitals, clinics, surgical centers, physician offices, and pharmacies. While the POC Coagulometer has received the CE Mark for use in the European Union, it is still pending approval in the United States.

“Perosphere Technologies aims to revolutionize coagulation testing by providing healthcare professionals with accurate and timely results,” said Dr. Stefan Zappe, Principal Investigator and Chief Technology Officer at Perosphere Technologies. “By providing physicians with the tools to make faster, better-informed treatment decisions, our technology has strong potential to significantly enhance patient care.”

Related Links:
Perosphere Technologies 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Coagulation Analyzer
CS-2400
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.